Aster Capital Management’s MacroGenics MGNX Stock Holding History

Aster Capital Management’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-88,059	Closed	-$107K	–	1210
2025 Q2	$107K	Buy	+88,059	New	+$128K	0.02%	503

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aster Capital Management's MGNX Position: Q3 2025 in Review

Aster Capital Management sold out of MacroGenics (MGNX) in Q3 2025, closing a stake of 88,059 shares — an estimated $107K sold.

Aster Capital Management first reported a position in MGNX in Q2 2025 and held it in 1 quarter. The position peaked at $107K in Q2 2025. 104 funds tracked by Wall St. Rank hold MGNX as of Q3 2025.

Aster Capital Management reported no remaining MacroGenics position as of Q3 2025 after selling out during the quarter.
Aster Capital Management sold 88,059 MacroGenics shares in Q3 2025, an estimated $107K.
Aster Capital Management first reported a position in MacroGenics in Q2 2025 and held it in 1 quarter.
Aster Capital Management's MacroGenics position peaked at $107K in Q2 2025.
104 funds tracked by Wall St. Rank held MacroGenics as of Q3 2025.

Based on Aster Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.